Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Medicenna Therapeutics Corp (MDNAF)

Medicenna Therapeutics Corp (MDNAF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 132,131
  • Shares Outstanding, K 76,798
  • Annual Sales, $ 0 K
  • Annual Income, $ -18,880 K
  • EBIT $ -13 M
  • EBITDA $ -13 M
  • 60-Month Beta 1.87
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 7.95
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.18
  • Most Recent Earnings $-0.04 on 07/31/24
  • Next Earnings Date 11/12/24 [--]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.04
  • Number of Estimates 1
  • High Estimate -0.04
  • Low Estimate -0.04
  • Prior Year -0.05
  • Growth Rate Est. (year over year) +20.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.5000 +18.67%
on 10/10/24
1.8915 -5.89%
on 11/01/24
+0.2500 (+16.34%)
since 10/07/24
3-Month
1.3600 +30.88%
on 10/01/24
1.9400 -8.25%
on 09/04/24
+0.2532 (+16.58%)
since 08/07/24
52-Week
0.2839 +526.98%
on 12/20/23
2.2000 -19.09%
on 06/03/24
+1.4500 (+439.39%)
since 11/07/23

Most Recent Stories

More News
Medicenna to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

MDNAF : 1.7800 (+3.46%)
MDNA.TO : 2.47 (+2.49%)
Medicenna to Present at the Bloom Burton & Co. Healthcare Investor Conference

TORONTO and HOUSTON, April 14, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced...

MDNAF : 1.7800 (+3.46%)
MDNA.TO : 2.47 (+2.49%)
MDNA : 0.1570 (-13.16%)
Medicenna Presents Preclinical Data Demonstrating Potent Immune Modulating Effects of an IL-2/IL-13 Dual Specific Cytokine at the 2021 AACR Annual Meeting

-- The IL-2/IL-13 dual specific cytokine selectively stimulates anti-cancer immune cells and inhibits M2a polarization of pro-tumoral macrophages

MDNAF : 1.7800 (+3.46%)
MDNA.TO : 2.47 (+2.49%)
MDNA : 0.1570 (-13.16%)
Medicenna Announces Preclinical Data on MDNA11 with Anti-PD-1 Therapy and Unveils Novel Bifunctional Superkines at the Cytokine-Based Cancer Immunotherapies Summit

-- MDNA11 and anti-PD-1 combination leads to complete responses in a murine solid tumor model

MDNAF : 1.7800 (+3.46%)
MDNA.TO : 2.47 (+2.49%)
MDNA : 0.1570 (-13.16%)
Medicenna Therapeutics Announces Upcoming Presentation at the AACR Annual Meeting 2021

TORONTO and HOUSTON, March 11, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced...

MDNAF : 1.7800 (+3.46%)
MDNA.TO : 2.47 (+2.49%)
MDNA : 0.1570 (-13.16%)
Medicenna Therapeutics to Present at Upcoming March Investor Conferences

TORONTO and HOUSTON, March 04, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced...

MDNAF : 1.7800 (+3.46%)
MDNA.TO : 2.47 (+2.49%)
MDNA : 0.1570 (-13.16%)
Medicenna to Present at the Cowen 41st Annual Healthcare Conference

TORONTO and HOUSTON, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced...

MDNAF : 1.7800 (+3.46%)
MDNA.TO : 2.47 (+2.49%)
MDNA : 0.1570 (-13.16%)
Medicenna to Present at the 10th Annual SVB Leerink Global Healthcare Conference

TORONTO and HOUSTON, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced...

MDNAF : 1.7800 (+3.46%)
MDNA.TO : 2.47 (+2.49%)
MDNA : 0.1570 (-13.16%)
Medicenna Reports Third Quarter Fiscal 2021 Financial Results and Operational Highlights

TORONTO and HOUSTON, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “Company") (NASDAQ: MDNA, TSX: MDNA), a clinical stage immuno-oncology company, today announced its...

MDNAF : 1.7800 (+3.46%)
MDNA.TO : 2.47 (+2.49%)
MDNA : 0.1570 (-13.16%)
Medicenna Establishes At-the-Market Sales Facility

TORONTO and HOUSTON, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA, TSX: MDNA), a clinical stage immuno-oncology company, announced...

MDNAF : 1.7800 (+3.46%)
MDNA.TO : 2.47 (+2.49%)
MDNA : 0.1570 (-13.16%)

Business Summary

Medicenna Therapeutics Corp is a clinical stage immuno-oncology company. It is engaged in developing engineered versions of IL-2, IL4 and IL13 cytokines called Superkines and Empowered Cytokines ECs for the treatment of cancer. Medicenna Therapeutics Corp is based in Toronto, Canada.

See More

Key Turning Points

3rd Resistance Point 1.9337
2nd Resistance Point 1.8668
1st Resistance Point 1.7937
Last Price 1.7800
1st Support Level 1.6537
2nd Support Level 1.5868
3rd Support Level 1.5137

See More

52-Week High 2.2000
Last Price 1.7800
Fibonacci 61.8% 1.4680
Fibonacci 50% 1.2420
Fibonacci 38.2% 1.0159
52-Week Low 0.2839

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar